• Prostatype Genomics opened subscriptions in a rights issue of units, each carrying warrants TO6 and TO7; subscriptions run through July 23.
• Each unit right gives one unit priced at SEK 0.8; each unit includes eight shares, two TO6 warrants, four TO7 warrants.
• The issue targets up to SEK 47.4 million; commitments cover SEK 43.2 million, or 91.3%.
• TO6 warrants are exercisable Sept. 1-15 at SEK 0.1 per share; potential proceeds about SEK 11.8 million.
• TO7 warrants have an event-driven exercise tied to Medicare approval; price 70% of VWAP, capped at SEK 0.2, floor SEK 0.1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prostatype Genomics AB published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.